Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved crawled time : 23:00 save search
NeoGames and Aristocrat Receive Final Regulatory Approvals on Proposed Acquisition
Published: 2024-04-18 (Crawled : 23:00) - globenewswire.com
NGMS | $29.45 0.07% 0.07% 210K
|
Technology Services
|
| O: 0.14%
H: 0.03%
C: -0.03%
acquisition
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Provident Financial Services, Inc. Receives Federal Reserve Board Approval for its Merger with Lakeland Bancorp, Inc.
Published: 2024-04-11 (Crawled : 23:00) - globenewswire.com
PFS | $15.52 2.11% 0.0% 940K
|
Finance
|
| O: 1.18%
H: 3.5%
C: 2.4%
LBAI | $12.85 1.98% 2.02% 5
|
Finance
|
| O: 0.36%
H: 4.91%
C: 3.84%
reserve approval for financial
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
Published: 2024-04-02 (Crawled : 23:00) - biospace.com/
VNDA | $4.63 -3.54% -3.67% 1.3M
|
Health Technology
|
| O: -2.43%
H: 0.0%
C: -2.74%
fanapt fda approval treatment
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Published: 2024-03-26 (Crawled : 23:00) - biospace.com/
MRK | $126.88 -0.05% 0.43% 4.7M
|
Health Technology
|
| O: 0.38%
H: 0.24%
C: -0.21%
fda group treatment hypertension
FDA Approves Potential 'Game Changer' for Pulmonary Arterial Hypertension
Published: 2024-03-26 (Crawled : 23:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
fda hypertension potential
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.1M
|
Health Technology
|
| O: 0.0%
H: 0.33%
C: -2.64%
fda approval
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)
Published: 2024-03-22 (Crawled : 23:00) - prnewswire.com
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
| Email alert
Add to watchlist
opsynvi fda first hypertension therapy
FDA Approves First Gene Therapy for Rare Pediatric Disease
Published: 2024-03-18 (Crawled : 23:00) - biospace.com/
PRGO | $30.49 1.43% 1.41% 840K
|
Health Technology
|
| O: 0.33%
H: 0.13%
C: -1.51%
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: 0.2%
H: 0.08%
C: -1.14%
ABT | News | $107.59 0.49% 0.33% 3.1M
|
Health Technology
|
| O: 1.71%
H: 0.36%
C: -2.52%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.81%
H: 0.0%
C: 0.0%
fda rare first disease therapy
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
MIRM | $24.42 1.03% 0.94% 420K
|
Health Technology
|
| O: 1.49%
H: 2.98%
C: -0.43%
fda pruritus approval treatment livmarli
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2024-03-07 (Crawled : 23:00) - biospace.com/
BGNE | $138.99 6.15% 5.95% 120
|
Health Technology
|
| O: -0.93%
H: 3.2%
C: 2.66%
fda brukinsa approval treatment
Home Federal Bancorp, Inc. of Louisiana Announces Receipt of Regulatory Approval for Dividend from Home Federal Bank and Approval of Stock Repurchase Program
Published: 2024-03-07 (Crawled : 23:00) - globenewswire.com
HFBL M | $11.6302 -0.08% -4.96% 1K
|
Finance
|
| O: 3.92%
H: 0.0%
C: -0.0%
approval repurchase program home
QuidelOrtho Receives Health Canada Approval for Quidel® Triage® PLGF Test for Laboratory Use in Canada
Published: 2024-03-06 (Crawled : 23:00) - biospace.com/
QDEL | News 4 | $40.4 3.38% 3.34% 1.2M
|
Health Technology
|
| O: 0.14%
H: 0.91%
C: -0.3%
quidel test health approval canada
Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
Published: 2024-03-04 (Crawled : 23:00) - prnewswire.com
EYEN | $0.5426 5.05% 6.09% 0
|
Health Technology
|
| O: -2.19%
H: 0.0%
C: -21.08%
fda ocular approval treatment pharmaceuticals therapeutics
Prologis Board of Directors Approves 10 Percent Increase in Quarterly Common Stock Dividend
Published: 2024-02-22 (Crawled : 23:00) - prnewswire.com
PLD | $104.83 0.72% 0.16% 3.3M
|
Finance
|
| O: 0.03%
H: 0.54%
C: -0.2%
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Published: 2024-02-20 (Crawled : 23:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
tecvayli fda approved treatment
FDA Decisions: Novartis and Roche Win Multiple-Allergy Indication for Xolair
Published: 2024-02-16 (Crawled : 23:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: 1.66%
H: 0.0%
C: -1.59%
PRGO | $30.49 1.43% 1.41% 840K
|
Health Technology
|
| O: -0.37%
H: 0.81%
C: -0.65%
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
ABT | News | $107.59 0.49% 0.33% 3.1M
|
Health Technology
|
| O: 0.88%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
fda xolair novartis roche
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
Published: 2024-02-15 (Crawled : 23:00) - globenewswire.com
AEZS | $1.97 0.73% 6K
|
Health Technology
|
| O: 1.08%
H: 0.0%
C: -3.0%
meeting
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
Published: 2024-02-15 (Crawled : 23:00) - globenewswire.com
AEZS | $1.97 0.73% 6K
|
Health Technology
|
| O: 1.08%
H: 0.0%
C: -3.0%
management meeting
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device Company’s International Reach Expanding with Latest Regulatory Approval
Published: 2024-02-08 (Crawled : 23:00) - biospace.com/
NXL | $1.625 -0.31% 13.33% 65K
|
|
| O: 4.26%
H: 0.0%
C: -8.87%
device approval reach international technology
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
EAST | $1.0835 16.17% 15.21% 100
|
Commercial Services
BOF | $1.17 6.36% 14.73% 15K
|
LUCY | $0.2545 9.93% 13.94% 66K
|
n/a
TSLA | News | $144.68 1.85% 9.01% 93M
|
Consumer Durables
BNED | $0.2064 2.64% 8.96% 1.4M
|
Retail Trade
HLTH | $0.15 6.38% 7.84% 21K
|
Your saved searches
Save your searches and get alerts when important news are released.